You are here: Industry Insights > Akeso

News List

Penpulimab, the Fifth Chinese PD-1 Monoclonal Antibody, was approved for Marketing PharmaSources/Yefenghong
August 25, 2021
On August 5, penpulimab (AK105) developed by Akeso, Inc. was approved for marketing, which is used to treat patients with relapsed or refractory classic Hodgkin's lymphoma (r/r cHL) after second-line systemic chemotherapy.
Akeso's Il-17A Monoclonal Antibody (Gumokimab) Completion Of Patient Enrollment In Phase II Clinical Trial For The Treatment Of Ankylosing Spondylitis prnasia
December 29, 2021
Today, Akeso, Inc. (09926.HK) announces that Gumokimab (IL-17A monoclonal antibody, AK111), an innovative drug independently developed by the Company for the treatment of active ankylosing spondylitis has been completed.
Akeso Announces Launch of U.S. Investigator-Initiated Study of Cadonilimab (PD-1/CTLA-4 Bispecific Antibody) prnasia
December 07, 2021
Today, Akeso, Inc. (9926.HK) announced that the company will support an investigator-initiated study (IIS) to evaluate the efficacy and safety of Akeso's novel, first-in-class anti-PD-1/CTLA-4 bispecific antibody, cadonilimab...
Penpulimab Monoclonal Antibody (PD-1) Obtains Marketing Approval in China prnasia
August 06, 2021
Akeso, Inc. announced that the anti PD-1 monoclonal antibody drug Penpulimab monoclonal antibody injection co-developed by the Company with Sino Biopharmaceutical Limited, has obtained marketing approval by the National Medical Products Administration ...
CD47 Monoclonal Antibody (AK117) Completed Phase I Dose Escalation Trial and Obtained Approval to Initiate Clinical Trial in Combination with Azacitidine for Treatment of Acute Myeloid Leukemia prnasia
July 13, 2021
Akeso, Inc. is pleased to announce that, CD47 monoclonal antibody (AK117), a second-generation novel drug for immuno-oncology therapy independently developed by the Company, has completed phase I dose escalation trial in Australia.
Akeso's Penpulimab Monoclonal Antibody Submitted BLA in the United States prnasia
May 25, 2021
On May 24, 2021, Akeso, Inc. announced that Penpulimab, an PD-1 monoclonal antibody drug co-developed by the Company with Sino Biopharmaceutical Limited, has submitted a Biologics License Application to the Food and Drug Administration of the ...
Metastatic Cervical Cancer Treatment Granted FDA Fast Track Designation americanpharmaceuticalreview
August 19, 2020
Akeso announced the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for AK104, a novel anti-PD-1/CTLA-4 bi-specific antibody, as monotherapy for the treatment of patients with recurrent or metastatic squamous cervical cancer ...
Akeso, Inc. Completes Series-D Private Financing for US$150 Million En-CPhI.CN
November 11, 2019
Akeso, Inc. announced the completion of its Series-D private financing for nearly US$150 million, which was co-led in investment by Loyal Valley Capital ("LVC") and Sino Biopharmaceutical Co. Ltd.